Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 20/20 | 0.85 |
| ▸ | CASP6 | P55212 | 18/20 | 0.85 |
| ▸ | CASP8 | Q14790 | 18/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17264147 | 0.92 | CASP3 (1.00) | CASP3CASP6CASP8 | |
| Emricasan SCHEMBL29714117 | 0.88 | CASP3 (1.00) | CASP3CASP6CASP8 | |
| Emricasan SCHEMBL3288801 | 0.88 | CASP3 (1.00) | CASP3CASP6CASP8 | |
| SCHEMBL17264146 | 0.88 | CASP3 (0.87) | CASP3CASP6CASP8 | |
| Emricasan SCHEMBL2724694 | 0.88 | CASP3 (1.00) | CASP3CASP6CASP8 | |
| SCHEMBL20750654 | 0.86 | CASP3 (0.73) | CASP3CASP6CASP8 | |
| SCHEMBL17264153 | 0.85 | CASP3 (0.83) | CASP3CASP6CASP8 | |
| SCHEMBL19785120 | 0.84 | CASP3 (0.92) | CASP3CASP6CASP8 | |
| SCHEMBL22026276 | 0.83 | CASP3 (0.89) | CASP3CASP6CASP8 | |
| SCHEMBL21180991 | 0.82 | CASP3 (0.88) | CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364054-A1 | METHODS FOR TREATING COVID-19 | MEDSTAR HEALTH, INC. | 2023-11-16 | — | — | US | disclosed |
| US-11654132-B2 | Methods for treating COVID-19 | MEDSTAR HEALTH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20220395488-A1 | METHODS FOR TREATING COVID-19 | MEDSTAR HEALTH, INC. | 2022-12-15 | — | — | US | disclosed |
| EP-3444011-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH EMRICASAN | Conatus Pharmaceuticals, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190022043-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CONATUS PHARMACEUTICALS INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-20170128519-A1 | CASPASE INHIBITORS FOR THE TREATMENT OF COLORECTAL CANCER | CONATUS PHARMACEUTICALS INC (US) | 2017-05-11 | — | — | US | disclosed |
| WO-2017079566-A1 | CASPASE INHIBITORS FOR USE IN THE TREATMENT OF LIVER CANCER | CONATUS PHARMACEUTICALS, INC. (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170100448-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CONATUS PHARMACEUTICALS INC (US) | 2017-04-13 | — | — | US | disclosed |
| US-20160213736-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE | CONATUS PHARMACEUTICALS, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2015175381-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CONATUS PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190022043-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CASP1, CASP5, CASP2 | CASP3 5/4885CASP6 4/4885CASP8 11/4885 |
| US-20170100448-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CASP1, CASP2, CASP5 | CASP3 6/4885CASP6 10/4885CASP8 8/4885 |
| US-20170128519-A1 | CASPASE INHIBITORS FOR THE TREATMENT OF COLORECTAL CANCER | CASP3, CASP1, CASP7 | CASP3 1/4885CASP6 6/4885CASP8 12/4885 |
| US-20160213736-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE | CASP1, SERPINB1, CASP2 | CASP3 8/4885CASP6 12/4885CASP8 15/4885 |
| US-20220395488-A1 | METHODS FOR TREATING COVID-19 | CASP1, IL1B, PYCARD | CASP3 32/4885CASP6 29/4885CASP8 20/4885 |
| US-20230364054-A1 | METHODS FOR TREATING COVID-19 | CASP1, IL1B, PYCARD | CASP3 32/4885CASP6 29/4885CASP8 20/4885 |
| US-11654132-B2 | Methods for treating COVID-19 | CASP1, IL1B, PYCARD | CASP3 32/4885CASP6 29/4885CASP8 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.